{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-23-000040","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.070904+00:00","generated_at":"2026-06-13T07:28:34.224739+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PTC Therapeutics appoints Pierre Gravier as CFO effective July 13, 2023","bullets":["Pierre Gravier, age 38, appointed CFO; previously managing director at Perella Weinberg Partners.","Annual base salary of $525,000; target annual bonus of 45% of base salary.","Received inducement equity: 26,000 RSUs (4-year vest) and option for 65,000 shares (4-year vest).","Severance: 15 months base salary plus health benefits if terminated without cause or for good reason.","Employment agreement includes perpetual confidentiality, 15-month non-compete/non-solicit."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-23-000040","json":"https://secwatch.observer/filing/0001070081-23-000040.json","markdown":"https://secwatch.observer/filing/0001070081-23-000040.md","text":"https://secwatch.observer/filing/0001070081-23-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000040/0001070081-23-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000040/tmb-20230713x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:28:34.224739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6f747b8ca4","claim":"Pierre Gravier was appointed as Chief Financial Officer at PTC THERAPEUTICS, INC..","evidence_excerpt":"On July 13, 2023, the Board of Directors of PTC Therapeutics, Inc. (the “Company”) appointed Pierre Gravier, age 38, as Chief Financial Officer, effective as of July 13, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000040/0001070081-23-000040-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}